Exo-Top

Exo-Top

NurExone Biologic Announces Preclinical Evidence of Structural Repair in Injured Spinal Cord Tissue following ExoPTEN Treatment

TORONTO and HAIFA, Israel, Aug. 20, 2025 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is pleased to announce new preclinical imaging results providing anatomical evidence consistent with structural repair of spinal cord following treatment with ExoPTEN. An imaging-based analysis of animals

Read More »
August 24, 2025

Architects of Tomorrow’s Regenerative Medicine Breakthroughs

Imagine a future where science picks up where nature Ileaves off—where a groundbreaking treatment regenerates damaged nerves, restoring movement after spinal cord injuries and reversing vision loss from optic nerve damage. This isn’t science fiction; it’s the future that biotechnology and regenerative medicine are striving to create. Transformative breakthroughs emerge

Read More »
August 20, 2025

NurExone’s Exosomes Show Stronger Healing Potential Than Industry Standard

TORONTO and HAIFA, Israel, Aug. 08, 2025 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) today announced that an independent study showed that exosomes produced by NurExone outperformed a recognized commercial industry standard in areas that strongly support key healing tasks including

Read More »
August 8, 2025

Set layout popup